After a long product portfolio transition, we forecast that Bristol-Myers could return to a period of sustained high teens earnings per share growth in 2007-2010. |
Lilly's current valuation still provides an attractive entry point. The stock trades at a modest 8% to 10% premium to its peers against 2006 and 2007 earnings and at a discount against our 2008 to 2010 forecast. |
Schering-Plough shares are most likely to be impacted by first quarter 2006 results. |
The U.S. case is more important because of the economic implications, ... a nice psychological boost but you can't extrapolate the U.S. ruling from this because of the different legal standards. |
The U.S. case is more important because of the economic implications, ... It [the U.K. ruling] is a nice psychological boost but you can't extrapolate the U.S. ruling from this because of the different legal standards. |
The U.S. case is more important because of the economic implications. [The U.K. ruling] is a nice psychological boost, but you can't extrapolate the U.S. ruling from this because of the different legal standards. |
The U.S. case is more important because of the economic implications. It (the U.K. ruling) is a nice psychological boost but you can't extrapolate the U.S. ruling from this because of the different legal standards. |
This is half the savings that Pfizer achieved with its recently announced program. |
We just can't get there. Maybe they see something we don't see. |
We think the downside risk here is modest. Merck has fundamental challenges ahead based on its base business. We really concluded the stock is trading incorporating these items. |